Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00141726
Other study ID # UMCC 3-31
Secondary ID IRBMED 2003-0590
Status Completed
Phase Phase 2
First received August 30, 2005
Last updated November 4, 2015
Start date October 2003
Est. completion date February 2009

Study information

Verified date November 2015
Source University of Michigan Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the effectiveness of etanercept in the treatment of patients with sub-acute lung injury following a bone marrow transplant. This study will also examine the toxicity of treatment with etanercept as well as whether there is an improved quality of life in these patients.


Description:

Lung or breathing problems can develop several months to years following a bone marrow transplant. In some cases, these breathing problems develop without any signs of germs or infection in the lungs. The name for this type of breathing problem is called "Sub-Acute Lung Injury". Sub-acute lung injury often develops many months, even years following a bone marrow transplant. It is often characterized by shortness of breath, cough, wheezing and fatigue.

Sub-acute lung injury can either lead to the formation of scar tissue in the lungs (making it difficult to take deep breaths), or it can cause the lungs to get weak (making people feel out of breath easily). Approximately 25 - 50% of patients with sub-acute lung injury may eventually die from the damage in their lungs. Typically, such patients die from infections that develop inside the damaged lungs.

In this study, treatment with an experimental drug called Etanercept will be used. (Enbrel). The physicians feel there is the possibility that Etanercept may help improve breathing. Breathing ability will be assessed prior to treatment as well as during and after treatment so that comparisons can be made.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date February 2009
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender Both
Age group 6 Years and older
Eligibility Inclusion Criteria:

- Recipients of allogeneic bone marrow, cord blood, or peripheral blood stem cell transplants are eligible

- Age >6 years and able to complete pulmonary function testing

- Patients with evidence of sub-acute, non-infectious pulmonary dysfunction (OLD or RLD)

- Recipients of sub-ablative transplant regimens are eligible

- Recipients of donor leukocyte infusions (DLI) post-transplant are eligible

- Patients must be > 100 days post transplant

Exclusion Criteria:

- Patients with hypotension requiring inotropic agents other than dopamine < 5mcg/ kg/ minute for blood pressure support.

- Patients with a positive quantitative bacterial culture from the BAL fluid (= 104 CFU/ ml is considered positive)

- Patients whose BAL fluid is positive for significant bacterial pathogens or pathogenic nonbacterial microorganisms (as defined by protocol) by special stain, culture or PCR analysis

- Patients who are enrolled on a phase I or phase II trial for the prophylaxis or treatment of GVHD (acute or chronic) within 7 days of study entry.

- Patients with known hypersensitivity to etanercept.

- Patients who are pregnant.

- Patients with CMV seropositivity at the time of study entry. Testing may include wither CMV PCR analysis or CMV pp65 testing.

- Evidence for multi-system organ failure.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Etanercept
Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.

Locations

Country Name City State
United States The University of Michigan Cancer Center Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
University of Michigan Cancer Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

Yanik GA, Mineishi S, Levine JE, Kitko CL, White ES, Vander Lugt MT, Harris AC, Braun T, Cooke KR. Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Ma — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percent of Patients With a Greater Than or Equal to 10% Improvement in FEV1, or FVC, and DLCO Response was defined as a greater than or equal to 10% improvement in the absolute value for FEV1 (for obstructive defects) or FVC (for restrictive defects), and DLCO (Diffusing Capacity of the Lungs for Carbon Monoxide) . week 12 post therapy Yes
Secondary Percentage of Participants That Experience Grade 3 to 4 Adverse Events To evaluate the toxicity of etanercept therapy in patients with sub-acute lung injury > 100 days post transplant, the percent incidence of grade 3 to 4 adverse events among evaluable patients was calculated. continuously (and week 4, week 8 and week 12, week 20) Yes
See also
  Status Clinical Trial Phase
Completed NCT03712215 - STUDY OF ELECTRICAL STIMULATION IN PULMONARY FUNCTION IN INTENSIVE CARE UNIT N/A
Completed NCT04582201 - Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2 Phase 1/Phase 2
Recruiting NCT01990456 - Strategies for Optimal Lung Ventilation in ECMO for ARDS: The SOLVE ARDS Study N/A
Completed NCT01167621 - Changes in Refractory Acute Respiratory Distress Syndrome (ARDS) Patients Under High Frequency Oscillation-ventilation N/A
Terminated NCT00233207 - IC14 Antibodies to Treat Individuals With Acute Lung Injury Phase 2
Completed NCT00029328 - Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation Phase 1/Phase 2
Completed NCT00004494 - Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis Phase 1
Completed NCT00000579 - Acute Respiratory Distress Syndrome Clinical Network (ARDSNet) Phase 3
Recruiting NCT03236272 - Establishment of a Biomarkers-based Early Warning System of Acute Respiratory Distress Syndrome (ARDS)
Withdrawn NCT04508933 - Comparison of Extra Vascular Lung Water Index in Covid-19 ARDS and "Typical"ARDS Patients
Completed NCT02273687 - Time-motion-mode Ultrasound Diaphragm Measures in Patients With Acute Respiratory Distress in Emergency Department N/A
Recruiting NCT03424798 - Measuring Heart and Lung Function in Critical Care N/A
Recruiting NCT01992237 - Measuring Energy Expenditure in ECMO (Extracorporeal Membrane Oxygenation) Patients N/A
Completed NCT00719446 - Evaluating Health Outcomes and QOL After ALI Among Participants of the ALTA, OMEGA, EDEN, and SAILS ARDS Network Trials N/A
Completed NCT00236262 - Effect of Positive Expiratory Pressure on Right Ventricular Function in Patients With Respiratory Distress Syndrome N/A
Completed NCT00157144 - Australia and New Zealand Adult Extracorporeal Membrane Oxygenation (ECMO) Audit 2005 N/A
Completed NCT00300248 - Long-Term Results in Mechanically Ventilated Individuals With Acute Lung Injury/Acute Respiratory Distress Syndrome N/A
Recruiting NCT00465374 - A Validation/Interventional Study on Stress Index in Predicting Mechanical Stress in ARDS Patients Phase 3
Completed NCT00094406 - Carbon Monoxide to Prevent Lung Inflammation Phase 1
Recruiting NCT03709199 - Long Term Follow up of Children Enrolled in the REDvent Study